SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •1. Previously treated with PI3K inhibitors or BTK inhibitors
• •2. Unresolved toxicity of CTCAE grade \> 1 from prior anti-lymphoma therapy
• •3. Chemotherapy or other investigational therapy within 28 days (or 5 times the half-life time, whichever is shorter) before starting cycle 1
• •4. Significant concurrent medical disease or condition which according to the investigators' judgement
• •5. Active hepatitis B, C or HIV infection
• •6. Infection requiring treatment 2 weeks prior to the first dosing